Esteve Pharmaceuticals SA - Company Profile
Powered by 
All the data and insights you need on Esteve Pharmaceuticals SA in one report.
$295
- Save hours of research time and resources with
our up-to-date Esteve Pharmaceuticals SA Strategy Report
- Understand Esteve Pharmaceuticals SA position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Esteve Pharmaceuticals SA Regulatory Milestones
Track drug and patent expiries along with geographies impacted.
A sample of Esteve Pharmaceuticals SA Regulatory Milestones data
| Drug Name | Generic Name | Brand Name | Company Name | Expiry Geography | Constraining Patent Number | Constraining Patent Expiry | Drug Expiry (Estimated) | Highest Development Stage |
|---|---|---|---|---|---|---|---|---|
| Deserunt mollit sunt Lorem | Lorem | Lorem | Pfizer Inc | Lorem | WXYZ | Lorem | Pending | Lorem |
| EGT-101 | - | - | Esteve Pharmaceuticals SA | United States | US8999948 | Jun-2031 | - | Phase II |
| EGT-101 | - | - | Esteve Pharmaceuticals SA | EU | EP2579900 | Jun-2031 | - | Phase II |
| (celecoxib + tramadol hydrochloride) | (celecoxib + tramadol hydrochloride) | - | Esteve Pharmaceuticals SA | United States | US8598152 | Apr-2030 | Apr-2030 | Marketed |
A sample of Esteve Pharmaceuticals SA Review Designation data
| Drug Name | Generic Name | Company Name | Indication | Geography | Designation Type | Designation Status | Designation Date |
|---|---|---|---|---|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | Lorem | Pfizer Inc | Lorem | Lorem | Lorem | Lorem | 15 Jan 2020 |
| Gene Therapy to Activate GALNS for Mucopolysaccharidosis IV | - | Esteve Pharmaceuticals SA | Mucopolysaccharidosis IV (MPS IV) (Morquio Syndrome ) | EU | Orphan Drug Designation | Designated | 09 Jan 2020 |
| EGT-201 | - | Esteve Pharmaceuticals SA | Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) | EU | Orphan Drug Designation | Designated | 24 Jan 2013 |
| EGT-201 | - | Esteve Pharmaceuticals SA | Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) | United States | Orphan Drug Designation | Designated | 27 Dec 2012 |
Feature
Regulatory Milestones provides an interactive, comprehensive, and analytical view of Drug and Constraining Patent Expiry and Exclusivity for Marketed and Pipeline (till preclinical development stage) pharmaceutical drugs in the United States (US), Europe (United Kingdom, Germany, France, Italy, and Spain) and Japan.
Benefit
Regulatory Milestones provides patent information for all novel Marketed and Pipeline pharmaceutical drugs available in the US, Europe (United Kingdom, Germany, France, Italy, and Spain) and Japan.
The Drug Expiry filters include Expiry Geography and Expiry Date as well as US-specific information.
The Drug Expiry date is based on the Constraining Patent Expiry, Patent Term Extension or Supplementary Protection Certificate (depending on the regulator), Exclusivity analysis and specific information on Review Designations granted by regulators.
US-specific information includes Exclusivity Type and Paragraph IV Certification filing under the Hatch Waxman Act (Paragraph IV).
Value
Regulatory Milestones is easily accessible and features a user-friendly platform. The tool includes attributes relating to Drug Expiry and Constraining Patents as well as attributes from Drugs and Companies .
Clients can utilize Regulatory Milestones to save time and effort through accumulated expiry information from various sources and registries in a standardized comparable format.
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer